Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy

Lieberman, Daniel Z.; Massey, Suena H.
January 2009
Core Evidence;2009, Vol. 4 Issue 1, p67
Academic Journal
Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. Aims: The objective of this article is to review the published evidence for the safety and efficacy of desvenlafaxine, and to compare it to other antidepressants to delineate its role in the treatment of depression. Evidence review: At the recommended dose of 50 mg per day the rate of response and remission was similar to other SNRIs, as was the adverse effect profile. The rate of discontinuation was no greater than placebo, and a discontinuation syndrome was not observed at this dose. Higher doses were not associated with greater efficacy, but they did lead to more side effects, and the use of a taper prior to discontinuation. The most common side effects reported were insomnia, somnolence, dizziness, and nausea. Some subjects experienced clinically significant blood pressure elevation. Place in therapy: Like duloxetine, desvenlafaxine inhibits the reuptake of both norepinephrine and serotonin at the starting dose. Dual reuptake inhibitors have been shown to have small but statistically significantly greater rates of response and remission compared to selective serotonin reuptake inhibitors, and they have also shown early promise in the treatment of neuropathic pain. Desvenlafaxine may prove to be a valuable treatment option by expanding the limited number of available dual reuptake inhibitors.


Related Articles

  • Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Deibert, Peter; Xander, Carola; Blum, Hubert E.; Becker, Gerhild // Core Evidence;2009, Vol. 4 Issue 1, p247 

    Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new...

  • Luliconazole for the treatment of fungal infections: an evidence-based review. Khanna, Deepshikha; Bharti, Subhash // Core Evidence;2014, Vol. 9, p113 

    Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this...

  • Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Krulig, Eliana; Gordon, Kenneth B. // Core Evidence;2010, Vol. 5 Issue 1, p11 

    Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated...

  • Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton, Katherine A. // Core Evidence;2009, Vol. 4 Issue 1, p191 

    Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the...

  • Effectiveness of Exercise Programs on Patients with Dementia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Xudong Li; Rui Guo; Zhenhong Wei; Jing Jia; Chaojun Wei // BioMed Research International;11/22/2019, p1 

    Exercise programs have been introduced to improve cognitive function, whereas studies showed inconsistent results regarding the effectiveness of exercise programs on patients with dementia. -is study aimed to summarize randomized controlled trials (RCTs) to assess the effect of exercise programs...

  • Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Gaffo, Angelo L.; Saag, Kenneth G. // Core Evidence;2009, Vol. 4 Issue 1, p25 

    Introduction: Gout is a common and disabling cause of arthritis in middle-aged and elderly populations, with its main predisposing factor being hyperuricemia (serum urate > 6.8 mg/dL). Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group...

  • Thunder-Fire Moxibustion for Cervical Spondylosis: A Systematic Review and Meta-Analysis. Huang, Ruina; Huang, Yunxuan; Huang, Ruijia; Huang, Shaofen; Wang, Xiaojun; Yu, Xiaojiang; Xu, Danghan; Chen, Xinghua // Evidence-based Complementary & Alternative Medicine (eCAM);2/11/2020, p1 

    Background. Cervical spondylosis (CS) refers to the degenerative changes in the cervical spinal column, which affect the majority of middle-aged and elderly people. Thunder-fire moxibustion originated from thunder-fire miraculous needle, which has been applied widely for treating pain syndromes...

  • Effects of Expiratory Muscle Strength Training on Videofluoroscopic Measures of Swallowing: A Systematic Review. Mancopes, Renata; Smaoui, Sana; Steele, Catriona M. // American Journal of Speech-Language Pathology;Feb2020, Vol. 29 Issue 1, p335 

    Purpose: Expiratory muscle strength training (EMST) is increasingly utilized in dysphagia rehabilitation; however, little is known about the effects of this approach on swallowing function or physiology. We conducted a systematic review to appraise and synthesize evidence regarding the effects...

  • Agomelatine: The evidence for its place in the treatment of depression. Eser, Daniela; Baghai, Thomas C.; Möller, Hans-Jürgen // Core Evidence;2009, Vol. 4 Issue 1, p171 

    Introduction: Depressive disorders are among the main causes of disability due to disease. In spite of recent progress in the pharmacotherapy of depression, there is still a high nonresponse rate of --30% to the first antidepressant treatment. Furthermore, the latency of several weeks until...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics